These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12875907)

  • 1. Delayed treatment with 5-nitro-6,7-dichloro-1,4-dihydro-2,3-quinoxalinedione, a glycine site N-methyl-D-aspartate antagonist, protects against permanent middle cerebral artery occlusion in male rats.
    Sarhan S; Wettstein JG; Maynard KI
    Neurosci Lett; 2003 Aug; 347(3):147-50. PubMed ID: 12875907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo neuroprotective effects of ACEA 1021 confirmed by magnetic resonance imaging in ischemic stroke.
    Petty MA; Neumann-Haefelin C; Kalisch J; Sarhan S; Wettstein JG; Juretschke HP
    Eur J Pharmacol; 2003 Aug; 474(1):53-62. PubMed ID: 12909195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed treatment with YM90K, an AMPA receptor antagonist, protects against ischaemic damage after middle cerebral artery occlusion in rats.
    Kawasaki-Yatsugi S; Shimizu-Sasamata M; Yatsugi S; Yamaguchi T
    J Pharm Pharmacol; 1998 Aug; 50(8):891-8. PubMed ID: 9751454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SM-31900, a novel NMDA receptor glycine-binding site antagonist, reduces infarct volume induced by permanent middle cerebral artery occlusion in spontaneously hypertensive rats.
    Ohtani K; Tanaka H; Ohno Y
    Neurochem Int; 2003 Apr; 42(5):375-84. PubMed ID: 12510020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A glycine site antagonist ZD9379 reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion.
    Tatlisumak T; Takano K; Meiler MR; Fisher M
    Acta Neurochir Suppl; 2000; 76():331-3. PubMed ID: 11450037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective effect of NMDA receptor glycine recognition site antagonism persists when brain temperature is controlled.
    Takaoka S; Bart RD; Pearlstein R; Brinkhous A; Warner DS
    J Cereb Blood Flow Metab; 1997 Feb; 17(2):161-7. PubMed ID: 9040495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo models of cerebral ischemia: effects of parenterally administered NMDA receptor glycine site antagonists.
    Warner DS; Martin H; Ludwig P; McAllister A; Keana JF; Weber E
    J Cereb Blood Flow Metab; 1995 Mar; 15(2):188-96. PubMed ID: 7860652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of glycine site antagonists of the NMDA receptor in global cerebral ischaemia.
    Hicks CA; Ward MA; Ragumoorthy N; Ambler SJ; Dell CP; Dobson D; O'Neill MJ
    Brain Res; 1999 Feb; 819(1-2):65-74. PubMed ID: 10082862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel NMDA/glycine site antagonists attenuate cocaine-induced behavioral toxicity.
    Matsumoto RR; Brackett RL; Kanthasamy AG
    Eur J Pharmacol; 1997 Nov; 338(3):233-42. PubMed ID: 9424017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of the glycine site-specific N-methyl-D-aspartate antagonist ACEA1021 on ischemic brain damage caused by acute subdural hematoma in the rat.
    Tsuchida E; Bullock R
    J Neurotrauma; 1995 Jun; 12(3):279-88. PubMed ID: 7473802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterisation of SB-221420-A - a neuronal Ca(2+) and Na(+) channel antagonist in experimental models of stroke.
    Campbell CA; Barone FC; Benham CD; Hadingham SJ; Harries MH; Harling JD; Hills JM; Lewis VA; Mackay KB; Orlek BS; White RF; Parsons AA; Hunter AJ
    Eur J Pharmacol; 2000 Aug; 401(3):419-28. PubMed ID: 10936502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced brain infarct volume and improved neurological outcome by inhibition of the NR2B subunit of NMDA receptors by using CP101,606-27 alone and in combination with rt-PA in a thromboembolic stroke model in rats.
    Yang Y; Li Q; Yang T; Hussain M; Shuaib A
    J Neurosurg; 2003 Feb; 98(2):397-403. PubMed ID: 12593629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effects depend on the model of focal ischemia following middle cerebral artery occlusion.
    Takamatsu H; Kondo K; Ikeda Y; Umemura K
    Eur J Pharmacol; 1998 Dec; 362(2-3):137-42. PubMed ID: 9874163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycine receptor antagonism. Effects of ACEA-1021 on the minimum alveolar concentration for halothane in the rat.
    McFarlane C; Warner DS; Nader A; Dexter F
    Anesthesiology; 1995 Apr; 82(4):963-8. PubMed ID: 7717569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypothermia but not NMDA receptor antagonism protects against stroke induced by distal middle cerebral arterial occlusion in mice.
    Liu CW; Liao KH; Tseng H; Wu CM; Chen HY; Lai TW
    PLoS One; 2020; 15(3):e0229499. PubMed ID: 32126102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.
    Shimizu-Sasamata M; Kawasaki-Yatsugi S; Okada M; Sakamoto S; Yatsugi S; Togami J; Hatanaka K; Ohmori J; Koshiya K; Usuda S; Murase K
    J Pharmacol Exp Ther; 1996 Jan; 276(1):84-92. PubMed ID: 8558460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preconditioning effect of (S)-3,5-dihydroxyphenylglycine on ischemic injury in middle cerebral artery occluded Sprague-Dawley rats.
    Nik Ramli NN; Omar N; Husin A; Ismail Z; Siran R
    Neurosci Lett; 2015 Feb; 588():137-41. PubMed ID: 25562631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of ACEA-1416: a potent systemically active NMDA receptor glycine site antagonist.
    Ilyin VI; Whittemore ER; Tran M; Shen KZ; Cai SX; Kher SM; Keana JF; Weber E; Woodward RM
    Eur J Pharmacol; 1996 Aug; 310(2-3):107-14. PubMed ID: 8884205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel AMPA receptor antagonist, YM872, reduces infarct size after middle cerebral artery occlusion in rats.
    Kawasaki-Yatsugi S; Yatsugi S; Takahashi M; Toya T; Ichiki C; Shimizu-Sasamata M; Yamaguchi T; Minematsu K
    Brain Res; 1998 May; 793(1-2):39-46. PubMed ID: 9630503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substituted analogues of GV150526 as potent glycine binding site antagonists in animal models of cerebral ischemia.
    Di Fabio R; Conti N; De Magistris E; Feriani A; Provera S; Sabbatini FM; Reggiani A; Rovatti L; Barnaby RJ
    J Med Chem; 1999 Sep; 42(18):3486-93. PubMed ID: 10479281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.